Detalhe da pesquisa
1.
Experiences of patients with peritoneal carcinomatosis-related complex care needs and their caregivers.
Gynecol Oncol
; 181: 68-75, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38141533
2.
Pilot randomized trial of an acceptance-based telehealth intervention for women with ovarian cancer and PARP inhibitor-related fatigue.
Gynecol Oncol
; 177: 165-172, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37708581
3.
Identification of distinct symptom profiles in patients with gynecologic cancers using a pre-specified symptom cluster.
Support Care Cancer
; 31(8): 485, 2023 Jul 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-37480403
4.
Comparing adult-child and spousal caregiver burden and potential contributors.
Cancer
; 128(10): 2015-2024, 2022 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35285946
5.
Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours.
Br J Cancer
; 126(7): 1027-1036, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34887522
6.
How does patient-centered communication in ovarian cancer care enhance patient well-being? A mixed methods study.
Gynecol Oncol
; 167(2): 261-268, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36057465
7.
Racial and ethnic disparities in cancer caregiver burden and potential sociocultural mediators.
Support Care Cancer
; 30(11): 9625-9633, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36190556
8.
Cancer patients' experiences with medicinal cannabis-related care.
Cancer
; 127(1): 67-73, 2021 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32986266
9.
Lived experiences of women reporting fatigue during PARP inhibitor maintenance treatment for advanced ovarian cancer: A qualitative study.
Gynecol Oncol
; 160(1): 227-233, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33190931
10.
Perceived patient-centered communication, quality of life, and symptom burden in individuals with ovarian cancer.
Gynecol Oncol
; 163(2): 408-418, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34454724
11.
Embedding a genetic counselor into oncology clinics improves testing rates and timeliness for women with ovarian cancer.
Gynecol Oncol
; 160(2): 457-463, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33229043
12.
Stepping into survivorship pilot study: Harnessing mobile health and principles of behavioral economics to increase physical activity in ovarian cancer survivors.
Gynecol Oncol
; 161(2): 581-586, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33637350
13.
Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee.
Gynecol Oncol
; 161(2): 502-507, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33612336
14.
Leveraging mobile health technology and research methodology to optimize patient education and self-management support for advanced cancer pain.
Support Care Cancer
; 29(10): 5741-5751, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-33738594
15.
Patterns and predictors of cancer-related fatigue in ovarian and endometrial cancers: 1-year longitudinal study.
Cancer
; 126(15): 3526-3533, 2020 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32436610
16.
Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial.
Gynecol Oncol
; 159(1): 72-78, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32771276
17.
Landscape of genomic alterations in cervical carcinomas.
Nature
; 506(7488): 371-5, 2014 Feb 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-24390348
18.
Threats of Bots and Other Bad Actors to Data Quality Following Research Participant Recruitment Through Social Media: Cross-Sectional Questionnaire.
J Med Internet Res
; 22(10): e23021, 2020 10 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33026360
19.
How does a single session group intervention improve sexual function in ovarian cancer survivors? A secondary analysis of effects of self-efficacy, knowledge and emotional distress.
Psychol Health Med
; 25(1): 110-120, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31167551
20.
Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer.
Gynecol Oncol
; 154(1): 95-101, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31118140